Compound · clinical trials

Platinol clinical trials

Also listed in trial records as Cisplatin /m^2, Platinol-AQ

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 73 trials in our Canada, Mexico, Israel, Spain, Australia, USA, France, Japan, South Korea, Taiwan, Germany, Poland, China, Italy, UK, Turkey, Ireland, Belgium, Brazil, Switzerland, Norway, Austria, Netherlands, Sweden, Singapore, Czechia, Denmark, Portugal, Egypt and India registers that name Platinol as an intervention. Synced 31 Oct 2026

73Current trials

30Recruiting now

20Lead sponsors

30Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 31 Oct 2026 · Editorial standards

At a glance

Platinol is named as an intervention in 73 current clinical trials in our Canada, Mexico, Israel, Spain, Australia, USA, France, Japan, South Korea, Taiwan, Germany, Poland, China, Italy, UK, Turkey, Ireland, Belgium, Brazil, Switzerland, Norway, Austria, Netherlands, Sweden, Singapore, Czechia, Denmark, Portugal, Egypt and India registers. 30 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is National Cancer Institute (NCI) (22). The most-studied condition is Non-small Cell Lung Cancer.

Patient leaflets for Platinol

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

Recruiting3041%
Active, closed4359%

Trials by phase

Phase 33649%
Phase 22433%
Phase 2/3710%
Phase 134%
Phase 1/211%
Observational11%
Not applicable11%

Clinical trials of Platinol

73 trials

Study	Phase	Status	Lead sponsor	Registers
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors NCT03067181 · ClinicalTrials.gov ↗ · Childhood Extracranial Germ Cell Tumor, Extragonadal Embryonal Carcinoma, Germ Cell Tumor	Phase 3	Recruiting	Children's Oncology Group	India, Canada, Mexico, Japan, Australia, Israel
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) NCT03126916 · ClinicalTrials.gov ↗ · Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma	Phase 3	Recruiting	Children's Oncology Group	Canada, Mexico, Israel
Induction Chemotherapy Followed by Standard Therapy in Cervical Cancer With Aortic Lymph Node Spread NCT03534713 · ClinicalTrials.gov ↗ · Cervical Cancer TNM Staging Regional Lymph Nodes (N)	Phase 3	Recruiting	University Hospital, Toulouse	France
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence NCT03583710 · ENSAT Stage I Adrenal Cortex Carcinoma, ENSAT Stage II Adrenal Cortex Carcinoma, ENSAT Stage III Adrenal Cortex Carcinoma	Phase 3	Recruiting	M.D. Anderson Cancer Center	Germany, France, Sweden, Poland
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) NCT04267848 · ClinicalTrials.gov ↗ · Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma	Phase 3	Recruiting	National Cancer Institute (NCI)	Norway, Mexico, Israel
Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL) NCT04574960 · ClinicalTrials.gov ↗ · Bladder Cancer, Bladder Urothelial Carcinoma	Phase 3	Recruiting	University Health Network, Toronto	Canada
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss NCT05382338 · Childhood Medulloblastoma	Phase 3	Recruiting	Children's Oncology Group	Canada, Israel
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer NCT05624996 · ClinicalTrials.gov ↗ · Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8	Phase 3	Recruiting	NRG Oncology	Canada, Mexico
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma NCT06172296 · ClinicalTrials.gov ↗ · Ganglioneuroblastoma, Nodular, Neuroblastoma	Phase 3	Recruiting	National Cancer Institute (NCI)	Canada, Mexico, Australia, Israel
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. NCT06431633 · ClinicalTrials.gov ↗ · Lung Diseases, Carcinoma, Non-Small-Cell Lung, Resectable Lung Non-Small Cell Carcinoma	Phase 3	Recruiting	Fundación GECP	Spain
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) NCT06623422 · Carcinoma, Non-Small-Cell Lung	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Israel
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer NCT07061977 · ClinicalTrials.gov ↗ · Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma	Phase 3	Recruiting	National Cancer Institute (NCI)	Mexico, Israel
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study NCT07097142 · ClinicalTrials.gov ↗ · Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8	Phase 3	Recruiting	NRG Oncology	Canada
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) NCT07190248 · Non-small Cell Lung Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) NCT07216703 · Cervical Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, India, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Israel
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer NCT04628767 · ClinicalTrials.gov ↗ · Renal Pelvis and Ureter Urothelial Carcinoma	Phase 2/3	Recruiting	National Cancer Institute (NCI)	Mexico
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery NCT02734537 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma	Phase 2	Recruiting	ECOG-ACRIN Cancer Research Group	Mexico
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma NCT04671667 · ClinicalTrials.gov ↗ · Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma	Phase 2	Recruiting	National Cancer Institute (NCI)	Mexico
Using ctDNA to Determine Therapies for Lung Cancer NCT04966663 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Complete Surgical Resection, Circulating Tumor DNA	Phase 2	Recruiting	University Health Network, Toronto	Canada
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) NCT05489211 · Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer	Phase 2	Recruiting	AstraZeneca	UK, USA, China, Germany, France, Spain, Italy, Poland, Switzerland, Turkey, Canada, Japan, South Korea, Taiwan
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio NCT05655949 · ClinicalTrials.gov ↗ · Bile Duct Cancer, Cholangiocarcinoma, Cholangiocarcinoma Non-resectable	Phase 2	Recruiting	Beth Israel Deaconess Medical Center	Israel
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer NCT06029270 · ClinicalTrials.gov ↗ · Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8	Phase 2	Recruiting	National Cancer Institute (NCI)	Canada, Singapore, Australia
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) NCT06064097 · ClinicalTrials.gov ↗ · Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8	Phase 2	Recruiting	National Cancer Institute (NCI)	Canada, Australia, Israel
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma NCT06140966 · ClinicalTrials.gov ↗ · Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma	Phase 2	Recruiting	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer NCT06532279 · ClinicalTrials.gov ↗ · Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	Phase 2	Recruiting	NRG Oncology	Mexico
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial NCT06770582 · ClinicalTrials.gov ↗ · Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8	Phase 2	Recruiting	National Cancer Institute (NCI)	Canada
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) NCT06428409 · Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China, Spain, Italy, Switzerland, Turkey, Canada, Japan, South Korea, Taiwan, Australia
A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer NCT02889666 · ClinicalTrials.gov ↗ · Recurrent Non-small Cell Lung Cancer	Phase 1	Recruiting	Shanghai Jiao Tong University School of Medicine	China, Japan
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer NCT05172245 · ClinicalTrials.gov ↗ · Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Carcinoma of Unknown Primary	Phase 1	Recruiting	National Cancer Institute (NCI)	Canada
Pathological Response After Neoadjuvant Treatment on NSCLC NCT05167487 · ClinicalTrials.gov ↗ · Stage IIIA Non-small Cell Lung Cancer	Observational	Recruiting	Fundación GECP	Spain
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma NCT00588770 · ClinicalTrials.gov ↗ · Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, Israel
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy NCT02445391 · ClinicalTrials.gov ↗ · Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma	Phase 3	Active, closed	ECOG-ACRIN Cancer Research Group	Mexico, Israel
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers NCT02466971 · ClinicalTrials.gov ↗ · Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma, Advanced Vaginal Squamous Cell Carcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) NCT03425643 · Non-small Cell Lung Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Italy, Belgium, Poland, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Egypt
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery NCT03533582 · ClinicalTrials.gov ↗ · Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma	Phase 3	Active, closed	Children's Oncology Group	Canada, Mexico, Australia, Israel
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) NCT03765918 · Head and Neck Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, Germany, France, Spain, Belgium, Poland, Switzerland, Austria, Portugal, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer NCT03775265 · ClinicalTrials.gov ↗ · Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8	Phase 3	Active, closed	National Cancer Institute (NCI)	Norway
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) NCT03811002 · ClinicalTrials.gov ↗ · Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8	Phase 3	Active, closed	National Cancer Institute (NCI)	Norway, Mexico, Japan, Egypt
Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer NCT03811015 · ClinicalTrials.gov ↗ · Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, Egypt
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer NCT04092283 · ClinicalTrials.gov ↗ · Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, Israel
CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC) NCT04116047 · Oropharyngeal Cancer	Phase 3	Active, closed	University of Birmingham	Ireland
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) NCT04380636 · Lung Neoplasms, Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China, Germany, France, Spain, Italy, Poland, Czechia, Norway, Turkey, Canada, Mexico, Japan, South Korea
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer NCT04595565 · HER2-negative Breast Cancer, Triple Negative Breast Cancer	Phase 3	Active, closed	GBG Forschungs GmbH	Ireland, Germany, France, Spain, Belgium, Switzerland, Austria
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) NCT04634877 · Endometrial Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Norway, Turkey, Canada, Mexico, Japan, South Korea, Taiwan, Israel
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) NCT04700124 · Bladder Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China, Germany, France, Spain, Italy, Poland, Czechia, Portugal, Canada, Japan, South Korea, Taiwan, Singapore, Australia, Israel
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) NCT05173987 · Endometrial Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Czechia, Norway, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008) NCT05224141 · Small Cell Lung Carcinoma	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Poland, Austria, Portugal, Turkey, Canada, Mexico, Japan, South Korea, Australia, Israel
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77) NCT05722015 · Metastatic Non-small Cell Lung Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	USA, China, France, Spain, Poland, Turkey, Brazil, Japan, Taiwan
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma NCT06097728 · Unresectable Pleural Mesothelioma	Phase 3	Active, closed	AstraZeneca	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Norway, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension NCT06212752 · ClinicalTrials.gov ↗ · Metastatic Non-small Cell Lung Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Japan
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma NCT06230224 · ClinicalTrials.gov ↗ · B-Cell Non-Hodgkin Lymphoma (B-NHL)	Phase 3	Active, closed	Regeneron Pharmaceuticals	Spain, Turkey, Brazil, South Korea, Taiwan, Singapore, Australia
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA NCT02135042 · ClinicalTrials.gov ↗ · EBV Infection, Stage II Nasopharyngeal Carcinoma AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7	Phase 2/3	Active, closed	NRG Oncology	China, Canada, Taiwan, Singapore, Australia
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer NCT03952585 · Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	Phase 2/3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico
Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer NCT04559139 · ClinicalTrials.gov ↗ · Stage II Gallbladder Cancer AJCC v8, Stage IIA Gallbladder Cancer AJCC v8, Stage IIB Gallbladder Cancer AJCC v8	Phase 2/3	Active, closed	ECOG-ACRIN Cancer Research Group	Mexico, Israel
Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer NCT05050162 · Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma	Phase 2/3	Active, closed	NRG Oncology	Ireland, Switzerland, Canada, Mexico
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers NCT05063552 · ClinicalTrials.gov ↗ · Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma	Phase 2/3	Active, closed	National Cancer Institute (NCI)	Mexico
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer NCT05800015 · Non-small Cell Lung Cancer	Phase 2/3	Active, closed	Regeneron Pharmaceuticals	USA, Turkey, Canada, Mexico, South Korea, Taiwan, Australia, Israel
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer NCT01585805 · ClinicalTrials.gov ↗ · Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8	Phase 2	Active, closed	National Cancer Institute (NCI)	Canada, Israel
Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer NCT01898494 · ClinicalTrials.gov ↗ · Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx	Phase 2	Active, closed	ECOG-ACRIN Cancer Research Group	Mexico
A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer NCT02151084 · ClinicalTrials.gov ↗ · Biliary Tract Carcinoma, Gallbladder Carcinoma	Phase 2	Active, closed	University Health Network, Toronto	Canada
Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas NCT02595424 · ClinicalTrials.gov ↗ · Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Carcinoma	Phase 2	Active, closed	ECOG-ACRIN Cancer Research Group	Mexico, Israel
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma NCT02724579 · ClinicalTrials.gov ↗ · Medulloblastoma	Phase 2	Active, closed	Children's Oncology Group	Canada, Australia, Israel
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial NCT04216290 · ClinicalTrials.gov ↗ · Bladder Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8	Phase 2	Active, closed	National Cancer Institute (NCI)	Mexico
Cisplatin+Pembrolizumab+RT in Vulvar Cancer NCT04430699 · ClinicalTrials.gov ↗ · Vulvar Cancer, Vulvar Squamous Cell Carcinoma	Phase 2	Active, closed	Massachusetts General Hospital	Israel
Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC NCT04630730 · ClinicalTrials.gov ↗ · Bladder Cancer	Phase 2	Active, closed	Swiss Cancer Institute	Switzerland
Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases NCT05012254 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Brain Metastases, Adult, Lung Cancer	Phase 2	Active, closed	Fundación GECP	Spain
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) NCT05186974 · Non-small Cell Lung Cancer	Phase 2	Active, closed	Gilead Sciences	UK, USA, Germany, France, Spain, Italy, Canada, South Korea, Taiwan, Australia
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer NCT05198830 · ClinicalTrials.gov ↗ · Lung Adenocarcinoma, Lung Large Cell Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Israel
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors NCT05945823 · Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer	Phase 2	Active, closed	Taiho Oncology, Inc	USA, Germany, France, Spain
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery NCT06161441 · Resectable Non-small Cell Lung Cancer	Phase 2	Active, closed	Regeneron Pharmaceuticals	USA, Germany, France, Spain, Italy, Turkey, South Korea, Taiwan, Australia
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) NCT06788912 · Lung Neoplasm Malignant	Phase 2	Active, closed	Merck Sharp & Dohme LLC	USA, Spain, Italy, Poland, Turkey
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer NCT04491942 · ClinicalTrials.gov ↗ · Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma, Advanced Cervical Carcinoma	Phase 1	Active, closed	National Cancer Institute (NCI)	Canada
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) NCT02194738 · ClinicalTrials.gov ↗ · Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8	Not applicable	Active, closed	National Cancer Institute (NCI)	Norway, Mexico, Israel

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with Platinol

156 conditions

Non-small Cell Lung Cancer4Stage III Lung Cancer AJCC v84Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v84Carcinoma, Non-Small-Cell Lung3 Bladder Cancer3Bladder Urothelial Carcinoma3Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v83Endometrial Neoplasms2 Non Small Cell Lung Cancer2Stage IIB Lung Cancer AJCC v82Stage II Bladder Cancer AJCC v82Stage IIIA Bladder Cancer AJCC v82

All 156 conditions

Condition (as registered)	Trials
Non-small Cell Lung Cancer	4
Stage III Lung Cancer AJCC v8	4
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	4
Carcinoma, Non-Small-Cell Lung	3
Bladder Cancer	3
Bladder Urothelial Carcinoma	3
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	3
Endometrial Neoplasms	2
Non Small Cell Lung Cancer	2
Stage IIB Lung Cancer AJCC v8	2
Stage II Bladder Cancer AJCC v8	2
Stage IIIA Bladder Cancer AJCC v8	2
Stage II Lung Cancer AJCC v8	2
Lung Non-Squamous Non-Small Cell Carcinoma	2
Stage IV Nasopharyngeal Carcinoma AJCC v8	2
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	2
Ganglioneuroblastoma, Nodular	2
Neuroblastoma	2
Head and Neck Squamous Cell Carcinoma	2
Recurrent Hypopharyngeal Squamous Cell Carcinoma	2
Recurrent Laryngeal Squamous Cell Carcinoma	2
Metastatic Non-small Cell Lung Cancer	2
Head and Neck Neoplasms	1
Advanced Head and Neck Squamous Cell Carcinoma	1
Advanced Hypopharyngeal Squamous Cell Carcinoma	1
Advanced Laryngeal Squamous Cell Carcinoma	1
Advanced Oropharyngeal Squamous Cell Carcinoma	1
Oropharyngeal Cancer	1
HER2-negative Breast Cancer	1
Triple Negative Breast Cancer	1
Cervical Cancer	1
Lung Neoplasms	1
Colorectal Cancer	1
Pancreatic Ductal Adenocarcinoma	1
Biliary Tract Cancer	1
Endometrial Cancer	1
Gastric Cancer	1
Metastatic Castration-resistant Prostate Cancer	1
Ovarian Cancer	1
Unresectable Pleural Mesothelioma	1
Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer	1
Esophageal Adenocarcinoma	1
Esophageal Squamous Cell Cancer	1
Siewert Type 1 GEJ Cancer	1
Lung Neoplasm Malignant	1
Resectable Non-small Cell Lung Cancer	1
Childhood Extracranial Germ Cell Tumor	1
Extragonadal Embryonal Carcinoma	1
Germ Cell Tumor	1
Malignant Germ Cell Tumor	1
Multiple Myeloma	1
Primary Plasma Cell Leukemia	1
Extramedullary Multiple Myeloma	1
EBV Infection	1
Stage II Nasopharyngeal Carcinoma AJCC v7	1
Stage III Nasopharyngeal Carcinoma AJCC v7	1
Stage IVA Nasopharyngeal Carcinoma AJCC v7	1
Recurrent Non-small Cell Lung Cancer	1
ENSAT Stage I Adrenal Cortex Carcinoma	1
ENSAT Stage II Adrenal Cortex Carcinoma	1
ENSAT Stage III Adrenal Cortex Carcinoma	1
Cervical Cancer TNM Staging Regional Lymph Nodes (N)	1
Stage IIIA Non-small Cell Lung Cancer	1
B-Cell Non-Hodgkin Lymphoma (B-NHL)	1
Brain Metastases, Adult	1
Lung Cancer	1
Lung Diseases	1
Resectable Lung Non-Small Cell Carcinoma	1
Stage IB Lung Non-Small Cell Carcinoma AJCC v7	1
Stage II Lung Non-Small Cell Cancer AJCC v7	1
Stage IIA Lung Cancer AJCC v8	1
Muscle Invasive Bladder Carcinoma	1
Limited Stage Lung Small Cell Carcinoma	1
Stage I Lung Cancer AJCC v8	1
Lung Non-Small Cell Carcinoma	1
Lung Non-Small Cell Squamous Carcinoma	1
Metastatic Nasopharyngeal Carcinoma	1
Recurrent Nasopharyngeal Carcinoma	1
Locally Advanced Pancreatic Adenocarcinoma	1
Metastatic Pancreatic Adenocarcinoma	1
Stage III Pancreatic Cancer AJCC v8	1
Stage IV Pancreatic Cancer AJCC v8	1
Muscle Invasive Bladder Urothelial Carcinoma	1
Childhood Hepatocellular Carcinoma	1
Childhood Malignant Liver Neoplasm	1
Fibrolamellar Carcinoma	1
Hepatoblastoma	1
Stage II Nasopharyngeal Carcinoma AJCC v8	1
Stage III Nasopharyngeal Carcinoma AJCC v8	1
Head and Neck Carcinoma of Unknown Primary	1
Locally Advanced Head and Neck Squamous Cell Carcinoma	1
Basaloid Squamous Cell Carcinoma	1
Oropharyngeal Squamous Cell Carcinoma	1
Biliary Tract Carcinoma	1
Gallbladder Carcinoma	1
Complete Surgical Resection	1
Circulating Tumor DNA	1
Childhood Medulloblastoma	1
Ganglioneuroblastoma	1
Medulloblastoma	1
Advanced Vaginal Adenocarcinoma	1
Advanced Vaginal Adenosquamous Carcinoma	1
Advanced Vaginal Squamous Cell Carcinoma	1
Cervical Adenocarcinoma	1
Non-Muscle Invasive Bladder Urothelial Carcinoma	1
Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma	1
Stage I Bladder Cancer AJCC v8	1
Locally Advanced Lung Non-Small Cell Carcinoma	1
Advanced Bile Duct Carcinoma	1
Advanced Breast Carcinoma	1
Advanced Cervical Carcinoma	1
Advanced Endometrial Carcinoma	1
Human Papilloma Virus Infection	1
Stage III Squamous Cell Carcinoma of the Oropharynx	1
Stage IVA Squamous Cell Carcinoma of the Oropharynx	1
Stage IVB Squamous Cell Carcinoma of the Oropharynx	1
Hypopharyngeal Squamous Cell Carcinoma	1
Laryngeal Squamous Cell Carcinoma	1
Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant	1
Stage II Gallbladder Cancer AJCC v8	1
Stage IIA Gallbladder Cancer AJCC v8	1
Stage IIB Gallbladder Cancer AJCC v8	1
Stage III Gallbladder Cancer AJCC v8	1
Locally Advanced Cervical Adenocarcinoma	1
Locally Advanced Cervical Adenosquamous Carcinoma	1
Locally Advanced Cervical Squamous Cell Carcinoma	1
Stage IIIA Cervical Cancer FIGO 2018	1
Stage III Bladder Cancer AJCC v8	1
Renal Pelvis and Ureter Urothelial Carcinoma	1
Recurrent Head and Neck Squamous Cell Carcinoma	1
Recurrent Oral Cavity Squamous Cell Carcinoma	1
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	1
Metastatic Head and Neck Squamous Cell Carcinoma	1
Metastatic Hypopharyngeal Squamous Cell Carcinoma	1
Metastatic Laryngeal Squamous Cell Carcinoma	1
Estrogen Receptor Negative	1
HER2/Neu Negative	1
Invasive Breast Carcinoma	1
Progesterone Receptor Negative	1
Neck Squamous Cell Carcinoma of Unknown Primary	1
Recurrent Laryngeal Verrucous Carcinoma	1
Recurrent Lung Non-Small Cell Carcinoma	1
Stage IIIA Lung Cancer AJCC v8	1
Stage IIIB Lung Cancer AJCC v8	1
Bile Duct Cancer	1
Cholangiocarcinoma	1
Cholangiocarcinoma Non-resectable	1
Cholangiocarcinoma Metastatic	1
Lung Adenocarcinoma	1
Lung Large Cell Carcinoma	1
Vulvar Cancer	1
Vulvar Squamous Cell Carcinoma	1
Small Cell Lung Carcinoma	1
Gastric Neuroendocrine Carcinoma	1
Intestinal Neuroendocrine Carcinoma	1
Pancreatic Neuroendocrine Carcinoma	1

By country register

Register	Trials	Recruiting
Clinical trials in Canada	36	17
Clinical trials in Mexico	32	12
Clinical trials in Israel	28	11
Clinical trials in Spain	23	7
Clinical trials in Australia	20	7
Clinical trials in USA	19	5
Clinical trials in France	18	6
Clinical trials in Japan	18	7
Clinical trials in South Korea	17	5
Clinical trials in Taiwan	17	5
Clinical trials in Germany	16	4
Clinical trials in Poland	15	5
Clinical trials in China	15	6
Clinical trials in Italy	15	5
Clinical trials in UK	14	5
Clinical trials in Turkey	14	4
Clinical trials in Ireland	9	2
Clinical trials in Belgium	9	3
Clinical trials in Brazil	9	3
Clinical trials in Switzerland	8	3
Clinical trials in Norway	8	1
Clinical trials in Austria	6	2
Clinical trials in Netherlands	5	2
Clinical trials in Sweden	5	3
Clinical trials in Singapore	5	2
Clinical trials in Czechia	5	1
Clinical trials in Denmark	4	1
Clinical trials in Portugal	3	0
Clinical trials in Egypt	3	0
Clinical trials in India	2	2

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Platinol trials

How many clinical trials are testing Platinol?

73 current trials in our Canada, Mexico, Israel, Spain, Australia, USA, France, Japan, South Korea, Taiwan, Germany, Poland, China, Italy, UK, Turkey, Ireland, Belgium, Brazil, Switzerland, Norway, Austria, Netherlands, Sweden, Singapore, Czechia, Denmark, Portugal, Egypt and India registers name Platinol (also registered as Cisplatin /m^2) as a drug or biological intervention, as of the registry sync on 31 October 2026. Completed and withdrawn studies are not counted.

Are Platinol trials recruiting patients?

Yes. 30 of the 73 trials are recruiting: 17 with sites in Canada, 12 with sites in Mexico, 11 with sites in Israel, 7 with sites in Spain, 7 with sites in Australia, 5 with sites in USA, 6 with sites in France, 7 with sites in Japan, 5 with sites in South Korea, 5 with sites in Taiwan, 4 with sites in Germany, 5 with sites in Poland, 6 with sites in China, 5 with sites in Italy, 5 with sites in UK, 4 with sites in Turkey, 2 with sites in Ireland, 3 with sites in Belgium, 3 with sites in Brazil, 3 with sites in Switzerland, 1 with sites in Norway, 2 with sites in Austria, 2 with sites in Netherlands, 3 with sites in Sweden, 2 with sites in Singapore, 1 with sites in Czechia, 1 with sites in Denmark and 2 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Platinol clinical trials?

National Cancer Institute (NCI) (22), Merck Sharp & Dohme LLC (14), NRG Oncology (5) and Children's Oncology Group (5), among 20 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Are there Platinol clinical trials in Ireland?

Yes. 9 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Platinol works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Platinol works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Platinol (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 31 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.